Search Results - "Terminiello, M." :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Clinical practice use of liquid biopsy to identify RAS/BRAF mutational status in patients with metastatic colorectal cancer: A single institution experience

Clinical practice use of liquid biopsy to identify RAS/BRAF mutational status in patients with metastatic colorectal cancer: A single institution experience

by De Falco, V., Vitiello, P., Giunta, E., Ciardiello, D., Stefania, N., Cardone, C., Vitale, P., Zanaletti, N., Terminiello, M., Poliero, L., Borrelli, C., Caputo, V., Arrichiello, G., Mattera Iacono, V., Marrone, F., Famiglietti, V., Martinelli, E., Ciardiello, F., Troiani, T.
Published in Annals of oncology (01.07.2019)

Get full text

Journal Article

$Retrospective study of Regorafenib versus Trifluridine/Tipiracil efficacy in chemorefractory metastatic colorectal cancer patients: a single Italian institution real-life clinical data$

Retrospective study of Regorafenib versus Trifluridine/Tipiracil efficacy in chemorefractory metastatic colorectal cancer patients: a single Italian institution real-life clinical data

by Vitale, P., Zanaletti, N., Vitiello, P., martinelli, e., Ciardiello, D., De Falco, V., Giunta, E., Poliero, L., Terminiello, M., Borrelli, C., Caputo, V., Arrichiello, G., Martini, G., Stefania, N., Famiglietti, V., Cardone, C., Ciardiello, F., Troiani, T.
Published in Annals of oncology (01.07.2019)

Get full text

Journal Article

A new natural compound identified through a metabolomic approach has cytotoxic activity against human colorectal cancer cell lines with acquired resistance to cetuximab

A new natural compound identified through a metabolomic approach has cytotoxic activity against human colorectal cancer cell lines with acquired resistance to cetuximab

by De Falco, V., Giunta, E.F., Belli, V., Matrone, N., Napolitano, S., Martinelli, E., Vitale, P., Zanaletti, N., Terminiello, M., Vitiello, P.P., Ciardiello, F., Troiani, T.
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

Receptor tyrosine kinase dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated colorectal cancer cell lines

Receptor tyrosine kinase dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated colorectal cancer cell lines

by Vitiello, P.P., Cardone, C., Ciardiello, D., Barra, G., Matrone, N., Belli, V., Martini, G., Poliero, L., Borrelli, C., Terminiello, M., Troiani, T., Morgillo, F., Ciardiello, F., Martinelli, E.
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

Macrophage migration inhibitory factor overexpression is a mechanism of acquired resistance to anti-EGFR inhibitor cetuximab in human colorectal cancer cell line

Macrophage migration inhibitory factor overexpression is a mechanism of acquired resistance to anti-EGFR inhibitor cetuximab in human colorectal cancer cell line

by Matrone, N., Chambery, A., Russo, R., Pedone, P.V., Belli, V., Napolitano, S., Martinelli, E., Giunta, E.F., De Falco, V., Zanaletti, N., Vitale, P., Terminiello, M., Cardone, C., Ciardiello, F., Troiani, T.
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

Combined inhibition of MEK and PI3KCA pathway induces synergic antitumor activity in HER2 amplified human colorectal cancer models

Combined inhibition of MEK and PI3KCA pathway induces synergic antitumor activity in HER2 amplified human colorectal cancer models

by Belli, V., Matrone, N., Napolitano, S., Martinelli, E., Castellone, M.D., Trusolino, L., Giunta, E.F., De Falco, V., Zanaletti, N., Vitiello, P.P., Ciardiello, D., Terminiello, M., Ciardiello, F., Troiani, T.
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

Efficacy of a multi-compartmental obesity prevention program (the 3P Project) in South Italy preschoolers

Efficacy of a multi-compartmental obesity prevention program (the 3P Project) in South Italy preschoolers

by Poeta, M, Massa, G, Di Salvio, D, Nuzio, S. Guercio, Pierri, L, Di Stasi, M, Savastano, R, Bisogno, A, Tripodi, M, Belmonte, F, Lausi, O, Alfano, G, Terminiello, M, Cersosimo, G, Savarese, G, Vajro, P
Published in Digestive and liver disease (08.10.2015)

Get full text

Journal Article

302P Clinical implication of tissue re-biopsy in metastatic breast cancer (MBC) patients: A single centre retrospective analysis

302P Clinical implication of tissue re-biopsy in metastatic breast cancer (MBC) patients: A single centre retrospective analysis

by Carlino, F., Diana, A., Terminiello, M., Ventriglia, A., Piccolo, A., Bruno, V., Lobianco, L., Caterino, M., Ciardiello, F., Daniele, B., Orditura, M.
Published in Annals of oncology (01.09.2021)

Get full text

Journal Article

397O Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study

397O Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study

by Martinelli, E., Martini, G., Troiani, T., Pietrantonio, F., Avallone, A., Normanno, N., Nappi, A., Maiello, E., Falcone, A., Santabarbara, G., Pinto, C., Santini, D., Ciardiello, D., Terminiello, M., Borrelli, C., Napolitano, S., Renato, D., Famiglietti, V., Esposito, L., Ciardiello, F.
Published in Annals of oncology (01.09.2020)

Get full text

Journal Article

13P Synergistic activity of PARP inhibitor and ATR inhibitor in melanoma cell lines may depend on BRAF-V600 mutation status

13P Synergistic activity of PARP inhibitor and ATR inhibitor in melanoma cell lines may depend on BRAF-V600 mutation status

by Giunta, E.F., Belli, V., Napolitano, S., De Falco, V., Vitiello, P.P., Terminiello, M., Caputo, V., Vitale, P., Zanaletti, N., Ciardiello, D., Argenziano, G., Martinelli, E., Martini, G., Troiani, T.
Published in Annals of oncology (01.09.2020)

Get full text

Journal Article

461P Real-time PCR-based assessment of RAS/BRAF mutations in the plasma of metastatic colorectal cancer (mCRC) patients: A single institution experience

461P Real-time PCR-based assessment of RAS/BRAF mutations in the plasma of metastatic colorectal cancer (mCRC) patients: A single institution experience

by Vitiello, P.P., De Falco, V., Giunta, E.F., Ciardiello, D., Canciello, M.A., Cardone, C., Vitale, P., Zanaletti, N., Borrelli, C., Poliero, L., Terminiello, M., Arrichiello, G., Caputo, V., Martini, G., Napolitano, S., Lombardi, A., Caraglia, M., Troiani, T., Ciardiello, F., Martinelli, E.
Published in Annals of oncology (01.09.2020)

Get full text

Journal Article

P-200 Bone metastases from colorectal cancer correlate with biological characteristics of primary tumors: A retrospective analysis from a single institution

P-200 Bone metastases from colorectal cancer correlate with biological characteristics of primary tumors: A retrospective analysis from a single institution

by Giunta, E., De Falco, V., Napolitano, S., Vitale, P., Zanaletti, N., Terminiello, M., Caputo, V., Vitiello, P., Ciardiello, D., Borrelli, C., Poliero, L., Arrichiello, G., Cardone, C., Martini, G., Martinelli, E., Ciardiello, F., Troiani, T.
Published in Annals of oncology (01.07.2020)

Get full text

Journal Article

P-199 Baseline neutrophil to lymphocyte ratio predicts survival in patients with metastatic colorectal cancer treated with cetuximab plus avelumab (CAVE) as a rechallenge strategy

P-199 Baseline neutrophil to lymphocyte ratio predicts survival in patients with metastatic colorectal cancer treated with cetuximab plus avelumab (CAVE) as a rechallenge strategy

by Ciardiello, D., Famiglietti, V., Napolitano, S., Terminiello, M., Borrelli, C., Vitiello, P., Pietrantonio, F., Avallone, A., Normanno, N., Maiello, E., Latiano, T., Cremolini, C., Santabarbara, G., Pinto, C., Santini, D., Esposito, L., Di Liello, A., Troiani, T., Ciardiello, F., Martinelli, E., Martini, G.
Published in Annals of oncology (01.07.2021)

Get full text

Journal Article

33PA new natural compound identified through a metabolomic approach has cytotoxic activity against human colorectal cancer cell lines with acquired resistance to cetuximab

33PA new natural compound identified through a metabolomic approach has cytotoxic activity against human colorectal cancer cell lines with acquired resistance to cetuximab

by De Falco, V, Giunta, E F, Belli, V, Matrone, N, Napolitano, S, Martinelli, E, Vitale, P, Zanaletti, N, Terminiello, M, Vitiello, P P, Ciardiello, F, Troiani, T
Published in Annals of oncology (01.10.2018)

Get full text

Journal Article

Phase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) colon

Phase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) colon

by Martinelli, E., Troiani, T., Cardone, C., Ciardiello, D., Zanaletti, N., Borrelli, C., Terminiello, M., Avallone, A., Falcone, A., Maiello, E., Bordonaro, R., Santini, D., Garufi, C., Pietrantonio, F., Pinto, C., Santabarbara, G., Normanno, N., Ciardiello, F.
Published in Annals of oncology (01.10.2019)

Get full text

Journal Article

Triple blockade of EGFR, MEK and PD-L1 as effective antitumor treatment in PD-L1 overexpressing, MEK inhibitor resistant colon cancer cells

Triple blockade of EGFR, MEK and PD-L1 as effective antitumor treatment in PD-L1 overexpressing, MEK inhibitor resistant colon cancer cells

by Matrone, N., Napolitano, S., Belli, V., Barra, G., Giunta, E.F., De Falco, V., Terminiello, M., Vitiello, P.P., Ciardiello, D., Turano, M., Furia, M., Muddassir, A.S., Kopetz, S., Martinelli, E., Ciardiello, F., Troiani, T.
Published in Annals of oncology (01.10.2019)

Get full text

Journal Article

127PIFN-γ/IL-10 ratio as predictive biomarker for response to anti-PD-1 therapy in metastatic melanoma patients

127PIFN-γ/IL-10 ratio as predictive biomarker for response to anti-PD-1 therapy in metastatic melanoma patients

by Giunta, E F, Barra, G, De Falco, V, Vitale, P, Zanaletti, N, Terminiello, M, Caputo, V, Napolitano, S, Vitiello, P P, Ciardiello, D, Belli, V, Brancaccio, G, Argenziano, G, De Palma, R, Ciardiello, F, Troiani, T
Published in Annals of oncology (01.10.2019)

Get full text

Journal Article

668TiP - Phase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) colon

668TiP - Phase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) colon

by Martinelli, E., Troiani, T., Cardone, C., Ciardiello, D., Zanaletti, N., Borrelli, C., Terminiello, M., Avallone, A., Falcone, A., Maiello, E., Bordonaro, R., Santini, D., Garufi, C., Pietrantonio, F., Pinto, C., Santabarbara, G., Normanno, N., Ciardiello, F.
Published in Annals of oncology (01.10.2019)

Get full text

Journal Article

668TiPPhase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) colon

668TiPPhase II study of avelumab in combination with cetuximab as a rechallenge strategy in pre-treated RAS wild type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) colon

by Martinelli, E, Troiani, T, Cardone, C, Ciardiello, D, Zanaletti, N, Borrelli, C, Terminiello, M, Avallone, A, Falcone, A, Maiello, E, Bordonaro, R, Santini, D, Garufi, C, Pietrantonio, F, Pinto, C, Santabarbara, G, Normanno, N, Ciardiello, F
Published in Annals of oncology (01.10.2019)

Get full text

Journal Article

11P - Triple blockade of EGFR, MEK and PD-L1 as effective antitumor treatment in PD-L1 overexpressing, MEK inhibitor resistant colon cancer cells

11P - Triple blockade of EGFR, MEK and PD-L1 as effective antitumor treatment in PD-L1 overexpressing, MEK inhibitor resistant colon cancer cells

by Matrone, N., Napolitano, S., Belli, V., Barra, G., Giunta, E.F., De Falco, V., Terminiello, M., Vitiello, P.P., Ciardiello, D., Turano, M., Furia, M., Muddassir, A.S., Kopetz, S., Martinelli, E., Ciardiello, F., Troiani, T.
Published in Annals of oncology (01.10.2019)

Get full text

Journal Article